The NHS spends approximately 10% (9.3bn) of its budget on branded drugs every year.1 Controlling this spending while maximising access to new pharmaceuticals, and encouraging innovation is challenging and ever more critical given the present financial constraints. The current Pharmaceutical Price Regulation Scheme (PPRS) seeks to limit pharmaceutical company profits but …
“Plain packaging” (also known as generic, standardised or homogenous packaging) means that all logos, graphics, and colours are removed from cigarette packs. …
Every night 1768 people sleep rough across England.1 Many of this population have complex health needs including mental health problems, drug misuse problems, …
Vitamin D deficiency is recognised as a significant public health problem. It is likely that deficiency is common in high risk groups …
In the UK approximately half of women drink alcohol during pregnancy, 8% drink above recommended safe limits (1 or 2 units once …
Point-of-sale marketing of tobacco, including tobacco display racks and sales incentives for retailers, has grown in importance to tobacco companies as other …
The Quality, Innovation, Productivity and Prevention (QIPP) programme is a large-scale programme developed by the Department of Health to drive forward quality …
Britain’s poorest families are set to miss out on support with their energy bills, putting the well-being and health of children at …
The coalition government remains committed to extending the role of competition in the NHS. It is hoped that market reforms encouraging competition …
Evidence based medicine is here to stay and has revolutionised the way clinicians around the world manage patients. At a recent surgical …